


Global pipeline of products for neglected diseases



Ongoing need

Lack of essential health technologies

- No HIV/AIDS vaccine
- TB treatment lasts 6–30 months, TB vaccine almost 100 years old
- No suitable treatments for Chagas, leishmaniasis, or mycetoma
- New disease threats continue to emerge



1 billion
PEOPLE AFFECTED BY
NEGLECTED DISEASES GLOBALLY


214 million

WOMEN HAVE UNMET NEED
FOR MODERN FAMILY PLANNING


6 million

ANNUAL DEATHS WORLDWIDE
FROM NEGLECTED DISEASES

Funding for neglected disease R&D



The return on investment of global health R&D



Critical US role in global health R&D


51%
of new global health products approved since 2000 were supported by the US government

40%
of late-stage products in the global health pipeline were supported by the US government

<.01%
of US GDP is spent annually on global health R&D

Top public funders of neglected disease R&D

(Investment as a percent of GDP)



While the US leads the world in funding for neglected disease R&D, these investments still account for less than .01% of US GDP



Infographic Data Sources

Global pipeline for neglected diseases

All data: Policy Cures Research. Neglected disease R&D product pipeline. 2017. Available from: <https://www.pipeline.policycuresresearch.org>

Funding for neglected disease R&D

R&D \$281 billion global spending on all health R&D: Røttingen, J-E, Regmi, S, Eide, M et al. Mapping of available health research and development data: what's there, what's missing and what role is there for a global observatory. *Lancet*. 2013; 383:1286–1307. [Data is for total global spending on health R&D in 2009 purchasing power parity-adjusted dollars, inflation adjusted to 2018 dollars.]

\$4 billion global spending on neglected disease R&D/Neglected disease R&D by sector: Chapman N, Doubell A, et al. Neglected Disease Research and Development: Uneven Progress. G-FINDER | 2019. Sydney: Policy Cures Research; 2019.

Return on investment in global health R&D

New health innovations resulted in 4.2 million fewer child deaths: Wang H, Liddell CA, Coates MM, et al. Global, regional, and national levels of neonatal, infant, and under-5 mortality during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. *The Lancet*. 2014.

Antiretroviral therapies prevented 7.8 million deaths: UNAIDS. AIDS by the numbers 2015. Geneva: UNAIDS; 2015.

\$.89 of every US dollar: Policy Cures Research, Global Health Technologies Coalition. Return on innovation: Why global health R&D is a smart investment for the United States. Sydney: Policy Cures Research; 2017.

€.80 of every euro: Policy Cures, Deutsche Stiftung Weltbevölkerung. Saving lives: Making the case for European investment in poverty-related and neglected disease R&D. Sydney: Policy Cures; 2016.

11% of economic growth in low-and middle-income countries: Jamison DT, Summers LH, Alleyne G, et al. Global health 2035: a world converging within a generation. *The Lancet*. 2013;382(9908):1859–1861.

US government investment in global health R&D from 2007–2015: Policy Cures Research, Global Health Technologies Coalition. Return on innovation: Why global health R&D is a smart investment for the United States. Sydney: Policy Cures Research; 2017.

\$26 million invested in polio vaccine R&D: Thompson KM, Tebbens RJ Retrospective cost-effectiveness analyses for polio vaccination in the United States. *Risk Anal*. 2006; 26(6):1423–40.

Every \$1 invested in HIV vaccine R&D: Hecht R, Jamison DT. Vaccine research and development assessment paper In: Lomborg B, ed. Rethink HIV: smarter ways to invest in ending HIV in sub-Saharan Africa. New York: Cambridge University Press, 2012; 299–320.

Meningitis A vaccine predicted to have saved \$9 billion: Stack M, Ozawa, S, Bishai, D, et al. Estimated Economic Benefits During The 'Decade Of Vaccines' Include Treatment Savings, Gains in Labor Productivity. *Health Affairs*. 2011.

The 2014 Ebola epidemic cost the US \$3 billion: Cost of the Ebola Epidemic |Ebola Hemorrhagic Fever |US Centers for Disease Control and Prevention [Internet]. [cited 2017 Mar 22]. Available from: <https://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/cost-of-ebola.html>

The 2014 Ebola epidemic cost the EU \$1.2 billion: EU response to the Ebola outbreak | European Commission [Internet]. [cited 2017 July 9]. Available from: https://ec.europa.eu/europeaid/regions/africa/west-africa/ebola-response_en

Pandemics could cost the world \$60 billion a year: Commission on a Global Health Risk Framework for the Future. The neglected dimension of global security: A framework to counter infectious disease crises. National Academy of Sciences. 2016.

Ongoing need

1 billion people affected by neglected diseases: World Health Organization (WHO). Investing to Overcome the Global Impact of Neglected Tropical Diseases: Third WHO Report on Neglected Tropical Diseases. Geneva: WHO; 2015.

6 million annual deaths from neglected diseases. Institute for Health Metrics and Evaluation (IHME). Global Burden of Disease Study 2010 (GBD 2010) Results by Cause and by Region 1990–2010. 2013.

214 million women have unmet family planning needs: Adding it Up: Investing in Contraception and Maternal and Newborn Health, 2017. New York: Guttmacher Institute, 2017.

Critical US role in global health R&D

All data: Policy Cures Research, Global Health Technologies Coalition. Return on innovation: Why global health R&D is a smart investment for the United States. Sydney: Policy Cures Research; 2017.

Top public funders of neglected disease R&D

All data: Chapman N, Doubell A, et al. Neglected Disease Research and Development: Uneven Progress. G-FINDER | 2019. Sydney: Policy Cures Research; 2019.